Hukyndra (Adalimumab)

Hukyndra is indicated for several chronic inflammatory and autoimmune disorders where tumor necrosis factor‑alpha plays a key role.

• Rheumatoid arthritis in adults.
• Psoriatic arthritis and plaque psoriasis.
• Ankylosing spondylitis.
• Moderate to severe Crohn’s disease.
• Ulcerative colitis unresponsive to conventional therapy.
• Hidradenitis suppurativa.

• Adalimumab is a fully human monoclonal antibody that selectively binds soluble and membrane‑bound tumor necrosis factor‑alpha (TNF‑α). By attaching to TNF‑α, it prevents the cytokine from interacting with its p55 and p75 cell‑surface receptors, thereby inhibiting downstream signaling pathways that drive inflammation, cell recruitment, and tissue destruction. This targeted blockade reduces the inflammatory cascade and complex immune responses.

Adalimumab may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common

• Redness, pain, or swelling at the injection site.
• Upper respiratory tract infections such as sinusitis or bronchitis.
• Headache, fatigue, or mild nausea.
• Mild injection site bruising or itching.

Serious

• Serious infections, including tuberculosis and opportunistic pathogens.
• Development of malignancies, particularly lymphomas or skin cancers.
• New or worsening heart failure, demyelinating disorders, or lupus‑like syndrome.
• Reactivation of hepatitis B in chronic carriers or other autoimmune hepatitis.

Patients should be monitored regularly, and any new symptoms reported promptly to a healthcare professional. These serious events, while uncommon, require immediate medical evaluation.

Before starting Hukyndra, certain health considerations and baseline assessments are recommended to minimize risks.

• Screen for latent tuberculosis and other chronic infections.
• Evaluate for active infections; postpone treatment if present.
• Review history of heart failure, demyelinating disease, or malignancy.
• Assess hepatitis B status and vaccinate if needed.
• Monitor complete blood count and liver function during therapy.
• Use caution in pregnancy or breastfeeding; discuss risks with a physician.
• Consider vaccination status; avoid live vaccines while on treatment.

Baseline laboratory tests, including CBC, liver enzymes, and hepatitis screening, are typically performed.

Adalimumab can interact with other medicines, affecting its efficacy or safety profile. These interactions may necessitate dosage adjustments, additional monitoring, or alternative therapeutic choices.

Avoid

• Live vaccines (e.g., measles, varicella) should be avoided because immunosuppression can cause infection.
• Do not combine with other TNF‑alpha inhibitors or biologics, as this raises infection risk.
• High‑dose corticosteroids or potent immunosuppressants require close supervision if used together.

Use with caution

• Anticoagulants such as warfarin may have an increased bleeding tendency; INR should be monitored regularly.
• Interferon‑beta or other immunomodulatory drugs may alter the therapeutic effect of adalimumab; monitor disease activity closely.
• Drugs metabolized by cytochrome P450 enzymes may require level checks, as adalimumab can indirectly affect their clearance.